Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines
Sarah A. Smith, … , Hiroshi Nakagawa, Gary D. Wu
Sarah A. Smith, … , Hiroshi Nakagawa, Gary D. Wu
Published November 3, 2020
Citation Information: J Clin Invest. 2021;131(1):e133371. https://doi.org/10.1172/JCI133371.
View: Text | PDF
Research Article Gastroenterology Inflammation

Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines

  • Text
  • PDF
Abstract

As the interface between the gut microbiota and the mucosal immune system, there has been great interest in the maintenance of colonic epithelial integrity through mitochondrial oxidation of butyrate, a short-chain fatty acid produced by the gut microbiota. Herein, we showed that the intestinal epithelium could also oxidize long-chain fatty acids, and that luminally delivered acylcarnitines in bile could be consumed via apical absorption by the intestinal epithelium, resulting in mitochondrial oxidation. Finally, intestinal inflammation led to mitochondrial dysfunction in the apical domain of the surface epithelium that may reduce the consumption of fatty acids, contributing to higher concentrations of fecal acylcarnitines in murine Citrobacter rodentium–induced colitis and human inflammatory bowel disease. These results emphasized the importance of both the gut microbiota and the liver in the delivery of energy substrates for mitochondrial metabolism by the intestinal epithelium.

Authors

Sarah A. Smith, Sayaka A. Ogawa, Lillian Chau, Kelly A. Whelan, Kathryn E. Hamilton, Jie Chen, Lu Tan, Eric Z. Chen, Sue Keilbaugh, Franz Fogt, Meenakshi Bewtra, Jonathan Braun, Ramnik J. Xavier, Clary B. Clish, Barry Slaff, Aalim M. Weljie, Frederic D. Bushman, James D. Lewis, Hongzhe Li, Stephen R. Master, Michael J. Bennett, Hiroshi Nakagawa, Gary D. Wu

×

Figure 1

The reciprocal relationship between short- and long-chain fatty oxidation by the colonic epithelium.

Options: View larger image (or click on image) Download as PowerPoint
The reciprocal relationship between short- and long-chain fatty oxidatio...
(A) Quantification of oleic acid oxidation using a tritiated water release assay in inverted colonic and small intestinal mouse explant cultures harvested from mice. n = 3, mean ± SEM, *P < 0.05. Representative results of at least 2–3 independent experiments. (B–E) Quantification of the fatty acid oxidation intermediates, acyl-CoAs, by mass spectrometry in mouse intestinal tissues. (B) Short- and (C) long-chain acyl-CoAs in the small intestine and colon. (D) Short- and (E) long-chain acyl-CoAs in the colon of wild-type versus SCAD-deficient mice. Representative results of at least 3 experiments. n = 5, mean ± SEM, *P < 0.05, **P < 0.01. (F) Quantification of oleic acid oxidation using the tritiated water release assay in colonic explants isolated from wild-type versus SCAD-deficient mice. n = 3, mean ± SEM, *P < 0.05. The assays were repeated in the presence or absence of 10 mM sodium butyrate in using colonic explants isolated from (G) wild-type or (H) SCAD-deficient mice. n = 3, mean ± SEM, *P < 0.05. Representative results of 2 independent experiments. P values represent a 2-tailed Student’s t test and paired-sample t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts